Carnegie Company Profile
What is the competitive landscape for CARNEGIE
CARNEGIE has twelve approved drugs.
Drugs and US Patents for Carnegie
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Carnegie | ERYPED | erythromycin ethylsuccinate | GRANULE;ORAL | 050207-003 | Mar 30, 1987 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Carnegie | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201942-001 | Nov 18, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Carnegie | LOMUSTINE | lomustine | CAPSULE;ORAL | 219265-002 | Oct 27, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Carnegie | LATANOPROST | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 202077-001 | Feb 11, 2013 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Carnegie | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | TABLET;ORAL | 061904-001 | Approved Prior to Jan 1, 1982 | BX | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Carnegie | VIGABATRIN | vigabatrin | TABLET;ORAL | 215519-001 | Apr 28, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

